-
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
Thursday, July 28, 2022 - 12:52pm | 979Read More...The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. Affecting an estimated 30% of U.S. veterans older than 65, aging frailty is characterized...
-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Wednesday, June 15, 2022 - 1:01pm | 1057Read More...Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron...
-
Who Is Donald Soffer And What Is His Legacy?
Monday, April 18, 2022 - 2:21pm | 700Read More...Miami-based Donald Soffer embodies the entrepreneurial spirit and vision of his ancestors who escaped Europe in search of opportunity in America. Here’s what you need to know about the 89-year-old billionaire businessman and his family. Childhood: Born Sept. 20, 1932, to immigrants of Polish...
-
Longeveron Partners With US Department Of Veterans Affairs For Its Phase 2 Alzheimer's Trial
Monday, April 18, 2022 - 8:39am | 590Read More...Photo by Caleb Fisher on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Longeveron Inc. (NASDAQ: LGVN) announced a Cooperative Research and Development Agreement (CRADA) with the United States...
-
Leading Medical Journal Publishes Study Of Longeveron's Phase 1 Trial Results For Alzheimer's Disease
Monday, April 4, 2022 - 8:00am | 882Read More...Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Longeveron Inc. (NASDAQ: LGVN) announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild...
-
Healthspan, Not Lifespan Should Be the Focus of Anti-Aging Research, Says Longeveron
Wednesday, March 30, 2022 - 8:40am | 1009Read More...This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As the world population gets older, healthcare professionals and scientists alike are increasingly stating that living longer is not enough. Medicine also...
-
Longeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress
Monday, March 14, 2022 - 10:23am | 4569Read More...Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer’s Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) Lomecel-B for HLSH Granted Rare Pediatric Disease and Orphan Drug...
-
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
Monday, December 6, 2021 - 10:13am | 1484Read More...HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per year Orphan Drug Designation confers certain benefits and may result in seven year market exclusivity upon approval for this indication if all statutory and regulatory requirements are met...
-
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
Monday, October 4, 2021 - 8:43am | 716Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Research and development of stem cell-based therapies, where a patient’s own cells, or those from a donor, are used to fight...
-
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
Wednesday, September 29, 2021 - 1:35pm | 1812Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent...
-
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
Thursday, September 9, 2021 - 8:42am | 1904Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. --Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month...
-
Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
Thursday, July 29, 2021 - 3:02pm | 934Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ:...
-
Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval
Wednesday, July 7, 2021 - 3:38pm | 1395Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative...
-
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
Thursday, June 24, 2021 - 9:10am | 1048Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. - Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease -...
-
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
Thursday, June 24, 2021 - 9:10am | 1048Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. - Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease -...
